Glycemic modulation in neuro-oncology: Experience and future directions using a modified Atkins diet for high-grade brain tumors

Neuro-Oncology Practice

Volumn 2, Issue 3, 2015, Pages 127-136

  Strowd, Roy E ^a   Cervenka, Mackenzie C ^a   Henry, Bobbie J ^a   Kossoff, Eric H ^a   Hartman, Adam L ^a   Blakeley, Jaishri O ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer metabolism; Glioma; Ketogenic diet; Modified Atkins diet; Seizure

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR; ISOCITRATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; PYRUVATE DEHYDROGENASE KINASE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN; SOMATOMEDIN C; TRICARBOXYLIC ACID;

ARTICLE; BIOCHEMICAL ANALYSIS; BRAIN TUMOR; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CYTOTOXICITY; DIET THERAPY; DISEASE COURSE; DRUG RESISTANT EPILEPSY; ENERGY METABOLISM; FOOD INTAKE; GLIOMA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; KETOACIDOSIS; KETOGENIC DIET; KETONURIA; MEDULLOBLASTOMA; METABOLISM; MODIFIED ATKINS DIET; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; TUMOR INVASION; WEIGHT REDUCTION;

EID: 85015682780     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npv010     Document Type: Article

References (83)

1. Johnson DR, O'Neil BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107(2):359-364.
2. Seyfried TN, Flores RE, Poff A, et al. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35(3): 515-527.
3. Warburg O. On the origin of cancer cells. Science. 1956;123: 309-314.
4. Oudard S, Arvelo F, Miccoli L, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996;74:839-845.
5. Fredericks M, Ramsey RB. 3-Oxo acid coenzyme A transferase activity in brain and tumors of the nervous system. J Neurochem. 1978;31: 1529-1531.
6. Tisdale MJ, Brennan RA. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer. 1983;47:293-297.
7. Oudard S, Arvelo F, Miccoli L, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996;74:839-845.
8. Maurer GD, Brucker DP, Bahr O, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;26(11):315.
9. Jelluma N, Yang X, Stokoe D, et al. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res. 2006;4(5):319-330.
10. Arismendi-Morilo GJ, Castellano-Ramirez AV. Ultrastructural pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies. J Electron Micros (Tokyo). 2008;57(1): 33-39.
11. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab (London). 2010;7:7.
12. Kiebish MA, Han X, Cheng H, et al. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res. 2008;49(12):2545-2556.
13. Takano T, Lin JH, Arcuino G, et al. Glutamate release promotes growth of malignant gliomas. Nat. Med. 2001;7:1010-1015.
14. de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011;59(8):1181-1189.
15. Zhou Y, Zhou Y, Shingu T, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286(37):32843-32853.
16. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature Rev Can. 2011;11:85-89.
17. Westhoff MA, Karpel-Massler G, Bruhl O, et al. A critical evaluation of PI3 K inhibition in Glioblastoma and Neuroblastoma therapy. Mol Cell Ther. 2014;2:32.
18. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892-3899.
19. Whiteman EL, Cho H, Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab. 2002;13(10):444-451.
20. Rathmell JC, Fox JC, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformational change and promote growth factor-independent survival. Mol Cell Biol. 2003;23(20):7315-7328.
21. Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3): 177-185.
22. Morfouace M, Lallier L, Oliver L, et al. Control of glioma cell death and differentiation by PKM2-Oct4 interaction. Cell Death Dis. 2014;5: e1036.
23. Poff AM, Ari C, Arnold P, et al. Ketone supplementation decreases tumor viability and prolongs survival of mice with metastatic cancer. Int J Cancer. 2014;135(7):1711-1720.
24. Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res. 2004;10(16):5622-5629.
25. Zhou W, Mukherjee P, Kiebish MA, et al. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab. 2007;4:5.
26. McDaniel SS, Rensing NR, Thio LL, et al. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011; 52(3):e7-11.
27. Seyfried TN, Sanderson TM, El-Abbadi MM, et al. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003;89(7):1375-1382.
28. Seyfried TN, Marsh J, Shelton LM, et al. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res. 2012;100(3):310-326.
29. Seyfried TN, Mukherjee P. Anti-angiogenic and pro-apoptotic effects of dietary restriction in experimental brain cancer: role of glucose and ketone bodies. In: Meadows GG, ed. Integration/Interaction of Oncologic Growth. New York, NY: Kluwer Academic; 2005:258-270.
30. Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLos One. 2012;7(5):e36197.
31. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond). 2010; 22(7):33.
32. Allen BG, Bhatia SK, Buatti JM, et al. Ketogenic diets enhance oxidative stress and radiochemotherapy response in lung cancer xenografts. Clin Cancer Res. 2013;19(14):3905-3913.
33. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30:3305-3316.
34. Raffaghello L, Safdie F, Bianchi G, et al. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010;9(22): 4474-4476.
35. Freeman JM, Freeman JB, Kelly MT. The Ketogenic Diet: A Treatment for Epilepsy, 3rd ed. New York, NY: Demos; 2000
36. Baranano KW, Hartman AL. The ketogenic diet: uses in epilepsy and other neurologic illnesses. Curr Treat Options Neurol. 2008;10(6): 410-419.
37. Henderson CB, Filloux FM, Alder SC, et al. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol March. 2006;21(3):193-198.
38. Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013;19(3):756-766.
39. Klein P, Tyrlikova I, Mathews GC. Dietary treatment in adults with refractory epilepsy: A review. Neurology. 2014;83(21):1978-1985.
40. Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade later. Pediatrics. 2007;119(3):535-543.
41. Kossoff EH, Pyzik PL, McGrogan JR, et al. Efficacy of the ketogenic diet for infantile spasms. Pediatrics. 2002;109:780-783.
42. Mady MA, Kossoff EH, McGregor AL, et al. The ketogenic diet: Adolescents can do it, too. Epilepsia. 2003;44:847-851.
43. Neal EG, Chaffe H, Schwartz RH, et al. A randomized trial of classical and MCT KDs in the treatment of epilepsy. Epilepseia. 2009;50(5): 1109-1117.
44. Pfiefer HH, Thiele EA. Low glycemic index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology. 2005;65(11):1810-1812.
45. Kossoff EH, Krauss GL, McGrogan JR, et al. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology. 2003;61(12): 1789-1791.
46. Kossoff EH, McGrogan JR, Bluml RM, et al. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia. 2006;47(2):421-424.
47. Kossoff EH, Cervenka MC, Henry BJ, et al. A decade of the modified Atkins diet (2003-13): Results, insights and future directions. Epilepsy Behav. 2013;29(3):437-442.
48. Kossoff EH, Rowley H, Sinha SR, et al. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia. 2008;49:316-319.
49. Cervenka MC, Terao NN, Bosarge JL, et al. Email management of the modified Atkins Diet for adults with epilepsy is feasible and effective. Epilepsia. 2012;53(4):728-732.
50. Porta N, Vallee L, Boutry E, et al. Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet. Seizure. 2009;18(5):359-364.
51. Kossoff EH, Dorward JL, Turner Z, et al. Prospective study of the modified Atkins diet in combination with a ketogenic liquid supplement during the initial month. J Child Neurol. 2011;26(2): 147-151.
52. Kossoff EH, Bosarge JL, Miranda MJ, et al. Will seizure control improve by switching from the modified Atkins diet to the traditional ketogenic diet? Epilepsia. 2010;51(12):2496-2499.
53. Fine EJ, Sega-Isaacson CJ, Feinman RD, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility trial in 10 patients. Nutrition. 2012;28(10): 1028-1035.
54. Schmidt M, Pfetzer N, Schwab M, et al. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011;8(1):54.
55. Rieger J, Bahr O, Maurer GD, et al. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843-1852.
56. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64: 6892-6899.
57. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24): 3838-3843.
58. Cervenka MC, Patton K, Eloyan A, et al. The impact of the modified Atkins diet on lipid profiles in adults with epilepsy. Nutr Neurosci. 2014;doi: 10.1179/1476830514Y.0000000162. [Epub ahead of print].
59. Brunner E, Stallone D, Juneja M, et al. Dietary assessment in Whitehall II: comparison of 7 d diet diary and food-frequency questionnaire and validity against biomarkers. Br J Nutr. 2001;86: 405-414.
60. Yang YJ, Kim MK, Hwang SH, et al. Relative validities of 3-day food records and the food frequency questionnaire. Nutr Res Pract. 2010;4(2):142-148.
61. Crawford PB, Obarzanek E, Morrison J, et al. Comparative advantage of 3-day food records over 24-hour recall and 5-day food frequency validated by observation of 9- and 10-year-old girls. J Am Diet Assoc. 1994;94(6):626-630.
62. Ambrosini GL, O'Sullivan TA, de Klerk NH, et al. Relative validity of adolescent dietary patterns: a comparison of a FFQ and 3-day food record. Br J Nutr. 2011;105(4):625-633.
63. Appannah G, Pot GK, O'Sullivan TA, et al. The reliability of an adolescent dietary pattern identified using reduced-rank regression: comparison of a FFQ and 3-day food record. Br J Nutr. 2014;112(4):609-615.
64. Kowalkowska J, Slowinska MA, Slowinski D, et al. Comparison of a full food-frequency questionnaire with the three-day unweighted food records in young Polish adult women: implications for dietary assessment. Nutrients. 2013;5(7):2747-2776.
65. Hedrick VE, Dietrich AM, Estabrooks PA, et al. Dietary biomarkers: advances, limitations and future directions. Nutr J. 2012;11:109.
66. Hartman AL, Rubenstein JE, Kossoff EH. Intermittent fasting: a "new" historical strategy for controlling seizures? Epilepsy Res. 2013;104(3):275-279.
67. Wong TZ, vann der Westheizen GJ, et al. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12(4):615-626.
68. QuW, Oya S, Lieberman BP, et al. Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors. J Nucl Med. 2012;53(1):98-105.
69. Chen W, Silverman DH, Delalove S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47(6):904-911.
70. Chan KW, McMahon MT, Kato Y, et al. Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med. 2012;68(6):1764-1773.
71. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997;10(1):2-12.
72. Alexander A, Murtha A, Abdulkarim B, et al. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med. 2006;29(5):301-311.
73. Wilson M, Cummins CL, Macpherson L, et al. Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours. Eur J Cancer. 2013;49(2):457-464.
74. Hourani R, Horská A, Albayram S, et al. Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging. 2006; 23(2):99-107.
75. Zhu H, Edden RA, Ouwerkerk R, et al. High resolution spectroscopic imaging of GABA at 3 Tesla. Magn Reson Med. 2011;65(3):603-609.
76. Zhu H, Soher BJ, Ouwerkerk R, et al. Spin-echo magnetic resonance spectroscopic imaging at 7 T with frequency-modulated refocusing pulses. Magn Reson Med. 2013;69(5):1217-1225.
77. Zhu H, Barker PB. MR spectroscopy and spectroscopic imaging of the brain. Methods Mol Biol. 2011;711:203-226.
78. Derr RL, Ye X, Islas MU, et al. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27(7):1082-1086.
79. Hong YJ, Han HS, Jeong Y, et al. Impact of hyperglycemia on survival and infection-related adverse events in patients with metastatic colorectal cancer who were receiving palliative chemotherapy. Cancer Res Treat. 2014;46(3):288-296.
80. Huang CW, Tsai JJ, Ou HY, et al. Diabetic hyperglycemia is associated with severity of epileptic seizures in adults. Epilepsy Res. 2008;79(1): 71-77.
81. Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012;7(5):e36197.
82. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
83. Mihavlova MM, Sabatini DM, Yilmaz OH. Dietary and metabolic control of stem cell function in physiology and cancer. Cell Stem Cell. 2014;14(3):292-305.